Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy

Pulmonary arterial hypertension is an unmet clinical need. Imatinib, a tyrosine kinase inhibitor, 200 to 400 mg daily reduces pulmonary artery pressure and increases functional capacity in this patient group, but is generally poorly tolerated at the higher dose. We have designed an open-label, singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Martin R., Mckie, Mikel A., Law, Martin, Roussakis, Andreas A., Harbaum, Lars, Church, Colin, Coghlan, J Gerry, Condliffe, Robin, Howard, Luke S, Kiely, David G, Lordan, Jim, Rothman, Alexander, Suntharalingam, Jay, Toshner, Mark, Wort, Stephen J, Villar, Sofía S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642118/
https://www.ncbi.nlm.nih.gov/pubmed/34868551
http://dx.doi.org/10.1177/20458940211052823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642118/
https://www.ncbi.nlm.nih.gov/pubmed/34868551
http://dx.doi.org/10.1177/20458940211052823

Ejemplares similares